Xcell Therapeutics KRX:373110KOSDAQ
엑셀세라퓨틱스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked4since Sep 11
In Q2 2026, Xcell Therapeutics reported revenue of ₩1.9bn, up 775.4% year on year, and an operating loss of ₩2.8bn. Xcell Therapeutics (엑셀세라퓨틱스) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Insider buying 4 quarters of losses Screener
Xcell Therapeutics quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.9bn | +775.4% | −₩2.8bn margin −142.2% | −₩2.8bn |
| Q1 2026 | ₩1.0bn | +209.8% | −₩2.9bn margin −285.2% | −₩2.9bn |
| Q4 2025 derived | ₩1.1bn | +123.2% | −₩3.3bn | −₩3.4bn |
| Q3 2025 | ₩335m | -26.9% | −₩2.4bn | −₩2.3bn |
| Q2 2025 | ₩221m | -53.7% | −₩2.7bn | −₩2.7bn |
| Q1 2025 | ₩330m | -36.8% | −₩2.6bn | −₩2.6bn |
| Q4 2024 derived | ₩477m | -2.2% | −₩2.5bn | −₩2.4bn |
| Q3 2024 | ₩458m | +54.0% | −₩2.7bn | −₩2.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Xcell Therapeutics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Xcell Therapeutics news Korean headlines
-
엑셀세라퓨틱스 "연내 신규 배지 4종 출시"
1 more on this story · 1 outlets
- 엑셀세라퓨틱스, 연내 신규 배지 4종 출시 본격화…"CGT 대응 파이프라인 완성"프라임경제 · Sep 15 08:45